Astellas Pharma Global Development, USA
Charles (Qianyong) Liu has over teen years of experience in biomarker R&D in oncology, CNS and cardiac diseases. Currently he is Principal Scientist at Astellas Pharma Global Development, responsible for developing and implementing translational biomarkers and delivering personalized medicine to support clinical trials in oncology and other therapeutic areas. He was Senior Research Scientist at Abraxis/Celgene where he served as tumor biomarker scientist and animal study manager in preclinical pipeline development. He completed his postdoctoral training in molecular genetics from Yale University and Howard Hughes Medical Institute. Dr. Liu received his PhD degree in Physiology from Cornell University and he is currently board certified by American Board of Toxicology and the Regulatory Affairs Professional Society.
Translational biomarker discover and development to support clinical trials
Pharmacogenomic biomarker development for patient stratification, drug safety and efficacy
Drug-companion diagnostics co-development using translational biomarkers